Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that FDA has granted fast track designation for its VX-880, an investigational human stem cell-derived islet cell therapy for type 1 diabetes.
Vertex has begun a clinical trial for VX-880 (formerly known as STx-02) in patients with type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness.
“Ours is the only approach that produces fully differentiated and fully functional insulin-secreting pancreatic islets,” said Bastiano Sanna, EVP and chief of Cell and Genetic Therapies at Vertex.
Get the full story on our sister site Drug Discovery and Development.
